Request for TOC Request for Sample
BUY NOW

Middle East and Africa Migraine Treatment Market – Industry Trends and Forecast to 2030

Healthcare | Upcoming Report | Feb 2023 | MEA | 350 Pages | No of Tables: 220 | No of Figures: 60
Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Middle East And Africa Migraine Treatment Market

Market Size in USD Billion

CAGR :  %

USD 65.83 Million USD 128.31 Million 2022 2030
Forecast Period
2023 –2030
Market Size(Base Year)
USD 65.83 Million
Market Size (Forecast Year)
USD 128.31 Million
CAGR
%
Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Middle East and Africa Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End-User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Middle East and Africa Migraine Treatment Market

Middle East and Africa Migraine Treatment Market Analysis and Size

Migraine is a common and debilitating brain illness. Headache accounts for 4.4 percent of all primary care visits, nearly 5% of all medical hospital admissions, and more than 20% of neurology outpatient consultations. Migraine affects approximately 20% of people at some point in their lives, according to epidemiological research, 4.5% of Western Europe's population suffers from headaches at least 15 days per month, and studies in the Middle East and Africa suggest that approximately 1% of the world's population suffers from chronic migraine. The vast majority of medications on the market now are approved to treat the acute version of the illness with generic triptans serving as the primary therapy. With the advent of CGRP-based medicines and the acceptance of novel medication classes such as ditans, gepants and the reformulation of triptans for both chronic and episodic migraine, the industry is observing a shift in terms of significant R&D.

Data Bridge Market Research analyses that the migraine treatment market which is USD 65.828 million in 2022, is expected to reach USD 128.31 million by 2030, at a CAGR of 8.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Middle East and Africa Migraine Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015- 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)

Countries Covered

Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Market Players Covered

Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Abbott (U.S.), Allodynic Therapeutics, LLC (U.S.), AOBiome (U.S.), AstraZeneca (U.K.), Aurobindo Pharma USA (U.S.), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S.), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S.), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S.)

Market Opportunities

  • Growing awareness regarding migraine

Market Definition

Migraine is a debilitating neurological disease characterized by recurrent severe throbbing head pain attacks lasting more than three days. Migraine affects approximately 15% of the population over their lifetime with women (18%) being more affected than men (8%). It has been dubbed the "seventh disabler" due to its significant impact on patients' quality of life (QOL).

Migraine Treatment Market Dynamics

Drivers

  •  Increase in migraine prevalence and diagnosis

An enormous increase in migraine cases is one of the key factors fuelling market expansion. Additionally, the industry is gaining from better migraine treatment reimbursement rules and the increased need for precision medications. The market is expanding due to rising demand for electrical nerve stimulators used to treat migraines and the anticipated approval of new classes of late-stage pipeline medications with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies.

  •  Significant progress is being made in the preventative treatment of chronic migraine

The important developments should force us to revaluate how we treat this terrible illness, encourage us to keep an eye out for new developments in clinical science, and remind us that only a coordinated clinical and scientific management approach will increase the identification of chronic migraines. The distinction between phenotypic and biological indicators sheds light on areas of clinical governance that have gone unnoticed. It is up to us to make sure that cutting-edge and evolving therapy options, including OBT-A and anti-CGRP monoclonal antibodies, are fully utilized within a larger preventative culture to significantly reduce the societal, monetary and individual costs of this fatal illness.

Opportunities

  • Growing awareness regarding migraine

The key factors influencing the growth of the Middle East and Africa migraine treatment market in the near future are the rising prevalence of migraines and the variety of available treatments. Many organisations, such as the American Headache and Migraine Association, are working to increase public awareness of migraine by creating programmes and offering patient support. These efforts aim to increase understanding of the condition and associated headache conditions. Many vendors will invest in migraine medications' research and development (R&D) due to the growing incidence of migraines and unmet needs in the Middle East and Africa migraine treatment market. As a result, during the forecast period of 2023 to 2030, the global market for migraine treatment is anticipated to expand.

Restraints/Challenges

  • Side effects associated with migraine treatment

The drop in clinical visits and procedural treatment of migraines due to social distance norms, limits of current migraine medicines, and alternative therapies such as homoeopathy are anticipated to hamper the market growth in the forecast period of 2023 to 2030.

This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Migraine Treatment Market

The neurologic manifestations of COVID-19 suggest that the virus may have entered the nervous system through the olfactory groove or the bloodstream. There is compelling evidence that COVID-19 mortality is linked to cardiac and pulmonary diseases. Furthermore, migraine increases the burden of vascular diseases, putting migraine sufferers at a higher risk of poor COVID-19 outcomes. Acute COVID-19 symptoms such as fever, sleep disturbance, and dehydration may precipitate a migraine attack. COVID-19 headaches were described as pulsating, pressing, or stabbing in quality were mostly bilateral, lasted longer, were resistant to analgesia and were more common in men. This makes migraine sufferers particularly vulnerable to the pandemic's chronic and indirect effects, such as low mood and post-viral fatigue. After the pandemic rising R&D spending resulting in massive pipeline products, as well as an increase in the prevalence of migraines with high unmet needs, are all contributing to the global growth of the migraine treatment market.

Recent Development

  • In 2022, According to Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc., Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, earned a favourable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).. The 75 mg dose of Rimegepant (available as an orally dissolving tablet) is suggested for marketing authorization for the acute treatment of migraine with or without aura in adults and the preventative treatment for episodic migraine in adults who experience at least four migraine attacks per month.
  • In 2022, Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.

Middle East and Africa Migraine Treatment Market Scope

The migraine treatment market is segmented on the basis of types, treatment, route of administration, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Episodic
  • Migraine with Aura
  • Chronic
  • Others 

Treatment

  • Acute/Abortive Treatment
  • Preventive/prophylactic Treatment 
  • Non-Pharmacological Therapies and Devices

Route of Administration

  • Oral
  • Parenteral

 Product

  • Prescription
  • Over The Counter

Type

  • Branded
  • Generic

 End-User

  • Hospitals
  • Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Migraine Treatment Market Regional Analysis/Insights

The migraine treatment market is analyzed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel and end-user as referenced above.

The countries covered in the migraine treatment market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

South Africa is dominating the Middle East and Africa migraine treatment market due to the sizable amount of businesses in this industry view the nation as a crucial manufacturing hub due to the advantages it provides. This gives the nation a significant manufacturing option in addition to being a significant consumer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The migraine treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for migraine treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the migraine treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and Migraine Treatment Market Share Analysis

The migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine treatment market.

Some of the major players operating in the migraine treatment market are:

  • Pfizer Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • GSK plc. (U.K.)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Abbott (U.S.)
  • Allodynic Therapeutics, LLC (U.S.)
  • AOBiome (U.S.)
  • AstraZeneca (U.K.)
  • Aurobindo Pharma USA (U.S.)
  • Bausch Health Companies Inc. (Canada)
  • Biohaven Pharmaceuticals (U.S.)
  • Boehringer Ingelheim International GmbH (Germany)
  • Catalent, Inc (U.S.)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Impel Pharmaceuticals Inc. (U.S.)
  • H. Lundbeck A/S (Denmark)
  • Merck & Co., Inc (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future